Alzheimer treatment compound found!

Alzheimer; News from the web:

Researchers from Cleveland Clinic’s Lerner Research Institute and Anesthesiology Institute found that the compound MDA7 induced beneficial immune responses that limited the development of Alzheimer’s disease.

Treatment with the compound restored cognition, memory and synaptic plasticity – a key neurological foundation of learning and memory – in an animal model.

“Cleveland Clinic dedicated two years of research into the examination of this compound and our findings show it could represent a novel therapeutic target in the treatment of Alzheimer’s disease,” Mohamed Naguib, lead researcher said in a statement.

Read all about it HERE

visit us at AlzheimerHeadlines.com

Epilepsy drug useful for Alzheimer?

News from the web:

Bearing in mind the note yesterday about the frequent hypes about wonder drugs to reverse Alzheimer’s disease, still we bring you today the news about a epilepsy drug that shows some promise in trails with animals. Lots of ifs and buts though as the Alzheimer is not the Human form but genetically modified and mice are not humans but still, we need some hope and continue to encourage research into novel ways to cure this terrible disease.

Read all about it HERE

visit us at AlzheimerHeadlines.com

Alzheimer in trading

News from the web:

With the disappointing news about the outcome of various clinical trails this month, the investors are looking how this shapes the trading environment in Alzheimer related companies for them. Follow the link to find a trading review that also, in reviewing the options for trading shows the current state of the trails and drug development for Alzheimer’s

Read all about it HERE

visit us at AlzheimerHeadlines.com

Multifunctional Drug also may help with Alzheimer’s

News from the web:

University Feinberg School of Medicine have developed a new “one-size-fits-all” therapy drug that could potentially treat Alzheimer’s, Parkinson’s disease, multiple sclerosis and traumatic brain injury

The drug’s trick lies in reducing a particular type of inflammation in the brain known as neuroinflammation.  This brain response has become increasingly considered a common denominator for many neurological disorders, as well as playing a major role in brain injuries.  To decrease inflammation, the drug developed at Northwestern binds to and decreases a molecule known as cytokine, which is released in large quantities during the neuroinflammatory response.
Read all about it HERE

visit us at AlzheimerHeadlines.com

Major setback in Alzheimer Drug quest

News from the web:

Pfizer said Monday that a highly anticipated experimental drug for Alzheimer’s disease, called bapineuzumab, wasn’t effective at slowing memory loss in a large, late-stage clinical trial in patients with a high-risk genetic mutation.

The negative result from this trial, the first of two late-stage trials on bapineuzumab to be announced this year, was expected by many scientists and investors, but it is nonetheless a disappointment to the companies and for the field of Alzheimer’s research.

Read all about it HERE

visit us at AlzheimerHeadlines.com

Food for Alzheimer’s

News from the web:

Nestle has bought a stake in U.S. firm Accera to support the rollout of a medical food brand for Alzheimer’s patients, as the world’s biggest food group seeks to expand in the health and nutrition business
Nestle said Axona provides an alternative energy source for Alzheimer’s patients, whose brains become less able to use glucose, resulting in improved memory and cognitive function, according to ongoing clinical trials.

Read all about it HERE

visit us at AlzheimerHeadlines.com